cDNA molecules encoding the structural proteins of the virulent Trinidad donkey and the TC-83 vaccine strains of Venezuelan equine encephalitis (VEE) virus were inserted under control of the vaccinia virus 7.5K promoter into the thymidine kinase gene of vaccinia virus. Synthesis of the capsid protein and glycoproteins E2 and E1 of VEE virus was demonstrated by immunoblotting of lysates of CV-1 cells infected with recombinant vaccinia/VEE viruses. VEE glycoproteins were detected in recombinant virus-infected cells by fluorescent antibody (FA) analysis performed with a panel of VEE-specific monoclonal antibodies. Seven E2-specific epitopes and two of four Elspecific epitopes were demonstrated by FA.
INTRODUCTION
Venezuelan equine encephalitis (VEE) virus is a mosquito-borne alphavirus which has caused numerous epidemics in equines and humans in the Americas. VEE virus infection often produces a fatal encephalitis in equines, with mortality and fatality rates in various epidemics of 19 to 40~ and 38 to 83 ~o, respectively (Groot, 1972) . Although the disease is generally milder in humans, with fatality rates lower than 1 ~, human morbidity can be significant. In particular, during the 1962 to 1964 VEE outbreak in Venezuela, an estimated 23 000 human cases occurred, with 960 cases of central nervous system infection and 156 deaths. In an epidemic in Ecuador in 1969, an estimated 31000 human cases occurred, with 310 deaths. Children under 15 years old are the most seriously affected (Groot, 1972) . Between 1969 and 1971, a VEE epizootic epidemic spread from South America through Central America and Mexico and reached the U.S.A. in 1971, causing over 1400 equine deaths in Texas (Lord, 1974) .
The live, attenuated TC-83 vaccine strain of VEE virus was derived from its virulent parent VEE strain, Trinidad donkey (TRD), by serial passage of TRD virus in embryonic guinea-pig heart cells (Berge et al., 1961) . The TC-83 vaccine proved invaluable in controlling the 1969 to 1971 epizootic of VEE in Central America (Walton et al., 1972; Eddy et al., 1972) and Texas (Calisher & Maness, 1975; Baker et al., 1978) . Although TC-83 virus is an effective vaccine, concerns remain about its possible reversion to virulence (Berge et al., 1961) and entry of the revertant into a mosquito-vertebrate host cycle (McKinney, 1972) . The reactogenicity of the TC-83 vaccine virus in humans (Alevizatos et al., 1967 ; McKinney et al., 1963) and the possible teratogenic potential of VEE virus (London et al., 1977) are also of concern. A formaldehydeinactivated preparation of TC-83 virus (C-84) has proven inferior to live, attenuated TC-83 virus 0000-8559 in protecting hamsters from peripheral or aerosol challange with virulent TRD virus (Jahrling & Stephenson, 1984) .
We have investigated expression of VEE virus proteins via recombinant vaccinia/VEE virus as a possible alternative VEE vaccine. The potential for success of this strategy was demonstrated by Rice et al. (1985) who obtained expression of the structural proteins of another alphavirus, Sindbis virus, in a recombinant vaccinia/Sindbis virus and by Franke et al. (1985) who showed that cattle immunized with recombinant vaccinia/Sindbis virus developed antiSindbis virus neutralizing antibody.
We have reported the cloning and sequencing of cDNA molecules containing the entire structural protein-coding region of the RNA genomes of VEE TRD and TC-83 viruses. We report here the construction of recombinant viruses, VACC/TC-83 and VACC/TRD, that express the structural proteins of these viruses.
METHODS

Cells and viruses.
Seed stocks of plaque-purified VEE viruses were prepared as frozen (-70 °C) aliquots of foetal bovine serum-enriched (12%) Eagle's MEM from virus-infected Vero cells. Vaccinia virus was the New York City Board of Health strain three times plaque-purified from a vial of smallpox vaccine (Dryvax, Wyeth Laboratories). Vaccinia virus and vaccinia/VEE recombinant virus stocks were grown in human 143B or CV-1 monkey cell cultures. Vero cell monolayers grown in six-well plates were used for virus plaque titrations. Overlay medium consisted of M-199 medium made with Earle's balanced salts solution, 2% (v/v) foetal bovine serum, 1% (w/v) Noble agar, 100 units/ml penicillin G, 100 gg/ml streptomycin sulphate and 0.12% (w/v) neutral red.
Construction of chimeric plasmid. Plasmid pGS-62, a derivative of the pGS-20 vector (Mackett & Smith, 1986; Mackett et al., 1984) with a single EcoRl site downstream of the vaccinia 7.5K promoter (Esposito et al., 1987) , was used for insertion ofcDNA encoding the structural proteins of VEE virus (Fig. 1) . Restriction enzyme Tthl 11I cleavage of pTC-5 , pTRD-1 or pTRD-20 (unpublished results) recombinant plasmids released the cDNA so that the translational start codon for the complete structural genes of VEE virus could be ligated into pGS-62 immediately downstream of the vaccinia virus 7.5K early-late promoter and mRNA start site by using EcoRl linkers. The mRNA transcript should initiate translation at the start codon and terminate at the UGA stop codon located at the end of the cDNA in glycoprotein El.
Insertion of VEEgenes into vaccinia virus. Recombinant vaccinia viruses were produced essentially as detailed by Mackett et al. (1982 Mackett et al. ( , 1984 . Recombinant virus was selected by plaque titration in TK-143B cell monolayers grown in six-well plates under overlay medium containing 30 gg/ml bromodeoxyuridine. Individual virus plaques were grown in 143B cell cultures in 24-well plates, and screened for the presence of VEE genes by DNA dot blot hybridization using nick-translated, 32p-labelled VEE-specific cDNA as probe. Recombinants were screened for expression by immune dot blotting. Recombinants were then plaque-purified three times in 143B cells in the presence of bromodeoxyuridine, and once in CV-1 cells without bromodeoxyuridine. CV-1 cell monolayers grown in Eagle's MEM supplemented with 10 % foetal bovine serum and antibiotics on 150 cm 2 flasks were infected with plaque-purified or recombinant vaccinia virus at a multiplicity of 0-05 p.f.u./cell. When c.p.e, was observed in 90% of the cells, they were harvested using a rubber policeman and pelleted by centrifugation at 6000 r.p.m, for 20 min in a GSA rotor. The cells were enucleated, trypsinized, homogenized and sonicated (three 30 s bursts at 50 W), and the virus was pelleted through a 40~ (w/w) sucrose cushion as described by Esposito et al. (1981) . The virus pellet was resuspended in TE buffer (10 mM-Tris-HCl pH 9.0, 1 mM-disodium EDTA) and stored at -70 °C until use.
Analysis of recombinant vaccinia/VEE virus genome structure. Genomic DNA was isolated from vaccinia or vaccinia/VEE recombinant virus as previously described (Esposito et al., 1981) . Restricted DNA was electrophoresed in 0.6% agarose in TBE buffer (1 M-Tris-HC1 pH 8.3, 0.91 M-boric acid, 20 mM-disodium EDTA) for 12 to 24 h at 30 V. Southern blotting and hybridization were performed as described by Maniatis et al. (1982) .
Preparation of VEE virus antisera. Polyclonal hyperimmune ascitic fluid to VEE TC-83 virus was prepared in NIH Swiss outbred mice as described by Hammon & Sather (1969) . The VEE virus monoclonal antibodies used in this study were prepared and characterized by Roehrig et al. (1982) .
Analysis of protein expression. VEE viral proteins were visualized by immunofluorescence or by immunoblotting of lysates of infected CV-1 cells. CV-1 cell monolayers (25 cm 2) were infected with virus (20 p.f.u./cell). At 18 h post-infection, lysates were prepared by washing cells with cold phosphate-buffered saline (PBS) and then adding 0.7 ml of RIPA buffer (1% w/v sodium deoxycholate, 1% v/v Triton X-100, 0-1% w/v SDS, 50 m•-Tris HC1 pH 7.4) containing 1% (v/v) aprotinin (Sigma) to each monolayer. Cell lysates were forced several times through a 25-gauge needle to shear DNA and then stored at -70 °C until use. For immunoblotting, aliquots of cell lysates were electrophoresed in 10 % (w/v) polyacrylamide-N,N'diallyltartardiamide (Bio-Rad) gels as described by . Polypeptides were transferred to nitrocellulose (Towbin et al., 1979) Indirect immunofluorescence tests for VEE proteins were done with CV-1 cells (four-or eight-chamber LabTek tissue culture slides, Miles Laboratories) infected with virus at a multiplicity of 10 or 20 p.f.u./cell. At 24 h post-infection, cell monolayers were rinsed twice with PBS and air-dried with or without prior acetone fixation. Expression of VEE virus epitopes was determined using acetone-fixed spot slides of virus-infected CV-1 cells that were scraped from 25 cm 2 flasks. Binding of virus-specific antibodies was detected with fluorescein isothiocyanate-conjugated goat anti-mouse IgG (Sigma).
RESULTS
Genome structure analysis of recombinant vaccinia/VEE viruses
Three recombinants were produced: VACC/TC-5A, expressing the genes encoding the structural proteins of VEE TC-83 virus, and two vaccinia/TRD virus recombinants, VACC/TRD-1A and VACC/TRD-20A, expressing the structural proteins of VEE TRD virus. (Fig. 2b) .
Expression of VEE structural proteins
Immunoblotting of VACC/TC-5A, VACC/TRD-1A and VACC/TRD-20A cell lysates clearly showed a polypeptide band that comigrated with the capsid protein in the VEE TC-83 and T R D cell lysates and in dissociated purified virions (Fig. 3) or TRD cDNA clones containing equivalent genomic regions, including the native VEE codons for initiation and termination of translation, we are unable to explain these differences in the expression of E2. There was no evidence of E 1, E2 or capsid polypeptide in lysates of uninfected or vaccinia virus-infected CV-1 cells (Fig. 3) . The polypeptide band intensities in Fig. 3 indicated that the level of VEE virus polypeptide expression in recombinant virus-infected CV-1 cells was severalfold lower than that in VEE virus-infected cells. Immune precipitation of radiolabeUed lysates showed the presence of pE2, the intracellular precursor to the E2 glycoprotein, in CV-1 cells infected with each of the recombinant viruses (data not shown). Expression of VEE proteins in recombinant virus-infected cells was demonstrated further by fluorescent antibody (FA) analysis using anti-TC-83 mouse hyperimmune ascitic fluid (1:200 dilution) (Fig. 4) . VEE antigens were detected in acetone-fixed and unfixed VEE TC-83 ( Fig. 4b and e respectively) and recombinant VACC/TC-5A (Fig. 4c andfrespectively) virus-infected CV-I cells. VEE antigens were not present in uninfected CV-I cells (Fig. 4a, d ). Although the level of expression of VEE structural proteins in recombinant virus-infected cells was lower than that in cells infected with VEE viruses (Fig. 3) , many recombinant virus-infected acetone-fixed ceils (Fig. 4c) showed FA intensity equal to that of TC-83 virus-infected cells (Fig. 4b) . Surface expression of VEE antigens as indicated by FA analysis of unfixed cells was lower in recombinant virus-infected cells (Fig. 4f ) than in cells infected with TC-83 virus (Fig. 4e) . Time course experiments showed that VACC/TC-5A or VACC/TRD-1A virus-infected CV-1 cells expressed FA-detectable levels of VEE antigen in fixed cells by 4 h post-infection. VEE TRD and VACC/TRD-1A virus-infected cells fluoresced to the same degree as TC-83 and VACC/TC-5A virus-infected cells, respectively (data not shown). 5B4D-6 E2 a TC-83
Expression of VEE glycoprotein epitopes
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* A l p h a n u m e r i c d e s i g n a t i o n s are a n t i -V E E virus m o n o c l o n a l antibodies (mouse ascitic fluids). E p i t o p e specificity a n d virus used to elicit m o n o c l o n a l a n t i b o d y are s h o w n . All a n t i b o d y p r e p a r a t i o n s w e r e tested at 1 : 300 dilution.
" well characterized monoclonal antibodies identifying epitopes in the E1 and E2 envelope glycoproteins of VEE virus (Roehrig et al., 1982; Roehrig & Mathews, 1985) enabled us to investigate expression of VEE virus-specific antigenic determinants in some detail (Table 1) . The antibody (2A4B-12) defining the E2 b epitope of VEE virus was unavailable for this study. The anti-E2 monoclonal antibodies shown in Table 1 generally reacted similarly with cells infected with VEE or vaccinia/VEE virus. In particular, the TC-83-specific antibody 5B4D-6 (epitope E2 a) (Roehrig et al., 1982; Roehrig & Mathews, 1985) also reacted more strongly with recombinant VACC/TC-5A-infected cells than with VACC/TRD-1A-infected cells. Monoclonal antibodies 1A4A-1 (E2°), 1A4D-1 (E2 f) and 1A3A-9 (E2g) showed positive FA reactivities with cells infected with VACC/TC-5A, VACC/TRD-1A, TC-83 or TRD virus. Although antibody 1A3A-5 (E2 e) reacted poorly with recombinant virus-infected cells, a pattern of TC-83 antigen specificity similar to that seen with VEE virus-infected cells was observed. Antibody 1A6C-3 (E2d), which reacted poorly with the cells expressing TC-83, TRD or VACC/TRD-1A virus antigens, failed to react with VACC/TC-5A virus-infected cells. The 1A3B-7 (E2 h) antibody failed to react well with VACC/TRD-1A recombinant-infected cells, while reacting strongly with cells infected with VACC/TC-5A, TC-83 or TRD virus.
Of the four E1 glycoprotein epitopes identified for VEE virus (Roehrig et al., 1982) , only the E1 b and E1 d epitopes were detected in recombinant VACC/TC-5A or VACC/TRD-1A virusinfected cells (Table 1) . Although the E1 a and E1 ~ epitopes were detected in VEE TC-83 and TRD virus-infected, acetone-fixed cells, these two epitopes were not evident by FA in recombinant VACC/TC-5A or VACC/TRD-1A virus-infected cells analysed under identical conditions.
DISCUSSION
The structural proteins of alphaviruses are translated as a polyprotein from a subgenomic 26S mRNA in the order 5'-capsid-E3-E2-6K-E 1-3' (Schlesinger & K/i/iri/iinen, 1980) . This precursor polyprotein is processed by proteolytic cleavage to produce capsid, E2 and E1 proteins which are incorporated into the mature virion. The short protein segments (E3, which is cleaved from pE2 to yield the E2 glycoprotein, and 6K) are cleavage products that are apparently not incorporated into mature VEE virions.
As shown for recombinant vaccinia virus expressing the structural proteins of Sindbis virus (Rice et al., 1985) , VEE mRNA was apparently transcribed in recombinant vaccinia/VEE virus-infected cells and translated into a polyprotein precursor that was processed to yield VEE structural proteins as cleavage products, thereby effectively mimicking translation of the 26S subgenomic mRNA in cells infected with VEE virus.
Indirect immunofluorescence using monoclonal antibodies demonstrated authentic expression of E2 a, E2 c, E2 e, E2 f, E2~, E1 b and E1 d epitopes in cells infected with recombinant VACC/TC-5A or VACC/TRD-1A virus. We are unable to explain the reduced expression of the E2 d epitope in VACC/TC-5A virus-infected cells. The pTRD-1 eDNA clone, however, encodes a Lys substitution in the E2 protein at amino acid position 209 (Glu in TRD genomic RNA) . It is possible that this cloning artefact may alter the binding efficiency of anti-E2 h monoclonal antibody to the E2 polypeptide expressed in VACC/TRD-1A virusinfected cells. The E1 a and E1 e epitopes, which were evident by FA in cells infected with VEE TC-83 or TRD virus, were not detected by FA (under identical conditions) in recombinant virus-infected cells. The reason for the apparent lack of expression of these two E 1 epitopes in recombinant virus-infected cells is as yet unknown.
Documentation of the expression of VEE surface glycoprotein epitopes in cells infected with recombinant vaccinia/VEE viruses has positive implications for the use of these recombinant viruses as alternative live, self-replicating VEE vaccines. Expression of the E2 c epitope is especially important because it defines the critical neutralization site of VEE virus (Roehrig et al., 1982; Roehrig & Mathews, 1985) . Earlier reports demonstrated that VEE E2 glycoprotein induces neutralizing and haemagglutination-inhibiting antibodies in immunized rabbits Trent et al., 1979) . Those epitopes (E2 °, E2 f, E2g and E2 h) which are defined by VEE-neutralizing monoclonal antibodies with different neutralization capacities are located in the same spatial domain on the glycoprotein spike (Roehrig et al., 1982; Roehrig & Mathews, 1985) . Mice passively immunized with monoclonal antibodies 1A4A-1 (E2C), IA3A-9 (E2o) and 1A3B-7 (E2h), which efficiently block attachment of VEE virus to cells in vitro (Roehrig et al., 1988) , are protected from lethal peripheral challenge with several virulent VEE subtype viruses (Roehrig & Mathews, 1985) . The E2 c and E2 h epitopes are the most conserved epitopes of the E2 glycoprotein among viruses of the VEE antigenic complex, and antibody elicited against these two epitopes should provide protection from heterologous VEE virus challenge.
Monoclonal antibody 3B2A-9 (El b) has a low level of neutralizing activity and protective capability in mice passively immunized against VEE virus (Roehrig et al., 1982; Mathews & Roehrig, 1982) . Passive administration of non-neutralizing anti-E ld monoclonal antibodies can prevent lethal encephalitis in mice (Mathews & Roehrig, 1982; Schmaljohn et al., 1982; Hunt & Roehrig, 1985) . These results indicate that expression of VEE epitopes E1 b and E1 d in addition to E2 epitopes by a genetically engineered vaccine may be a more effective immunogen than recombinant vaccines that express E2 antigenic determinants alone. Experiments are now in progress to determine the protective efficacy of the recombinant VACC/TC-5A virus in iinmunized mice.
